ArriVent BioPharma: announces publication of Phase 1b firmonertinib results

What happened On Oct 19, 2026 ArriVent BioPharma, Inc. issued a press release announcing the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell. The company filed a copy of the press release as Exhibit 99.1 to the Form 8-K.

Key details

• Item reported: 7.01 Regulation FD disclosure.
• Publication: results published in Cancer Cell, relating to FURMO-002 (NCT05364073).
• Press release date: Oct 19, 2026; filed as Exhibit 99.1 to the Form 8-K.

Why it may matter Item 7.01 covers Regulation FD disclosure and, in this filing, documents that the company announced the publication of clinical trial results via a press release. This filing does not show why an insider traded or why the company acted.